CBX-663 treatment for blood, solid tumor, or brain cancers that returned after treatment
This trial tests a new drug, CBX-663, for people with certain blood cancers, advanced solid tumors, or a type of brain cancer called glioblastoma that has returned or not responded to standard treatment. The goal is to see if the drug is safe and if it helps shrink tumors or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of the following: acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), advanced solid tumors that progressed after standard treatment, or recurrent glioblastoma (a brain cancer).
- Your cancer has come back or did not respond to standard therapy.
- You have a specific genetic marker called HLA-A*02:01 (blood test required).
- You are in good physical condition (able to do light activity).
- Your kidney and liver function are within acceptable limits (blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, DXC006, for people with advanced solid tumors or blood cancers like multiple myeloma and neuroblastoma that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
A trial testing an experimental drug (UBX-303061) for people with certain B-cell blood cancers (like CLL, DLBCL, or MCL) that have returned or not responded to at least two other treatments. The goal is to see if the drug is safe and works when other options are no longer available.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.